Ablynx Announces Update on Anti-RSV Nanobody Programme and Receives Grant Funding for Further Development

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GHENT, Belgium, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] today announced that it has received notice of a €1.68 million in grant funding from the Flemish Agency for Innovation by Science and Technology (IWT) to help advance the Company's first inhaled Nanobody®, ALX-0171, in infants. The grant funding, which is available over a period of one year, will also be used to explore novel applications of nebulised Nanobodies.

Help employers find you! Check out all the jobs and post your resume.

Back to news